Dr. Reddy’s Delays Semaglutide Production

Dr. Reddy’s Laboratories has delayed the commercial production and supply of its generic version of Ozempic, which is based on the drug semaglutide. The company disclosed the decision in a regulatory filing, stating that the pause affects commercial production and will delay supplies of the product. The move comes as the company addresses quality concerns identified during its checks on the product.

In its filing, the Indian pharmaceutical company said that certain batches of semaglutide were found to be out of specification. The deviation from required standards led management to halt commercial production while the issue is examined and corrected. This means the product will not move into the market as initially planned until those concerns are resolved.

Dr. Reddy’s linked the problem to the active pharmaceutical ingredient used in some batches of the semaglutide product. The company reported that the out-of-specification findings were associated with the active pharmaceutical ingredient, which is a critical component that determines the medicine’s safety and effectiveness. Identifying the ingredient as the source of the quality issue has made it the focus of the ongoing review.

The company said it is investigating the root cause of the ingredient-related problem. This involves examining why the affected batches fell outside defined quality specifications and what in the ingredient supply or handling may have contributed to the deviation. Understanding the root cause is necessary before production can resume with confidence in the product’s consistency.

Dr. Reddy’s stated that it is taking appropriate measures to ensure product quality in response to the findings. While specific corrective steps were not detailed, the company emphasized that actions are being taken to address the active ingredient issue and to prevent recurrence. These measures are aimed at bringing future batches back within specification before any commercial rollout.

The delay in commercial production means that supplies of the generic Ozempic product will be postponed until the investigation and corrective work are completed. The company has not provided a timeline for when production will resume or when supplies might reach the market. For now, the focus remains on resolving the quality issue tied to semaglutide’s active pharmaceutical ingredient before proceeding with broader commercialization.